WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Wedbush PacGrow 2021 Virtual Healthcare Conference

Format: Panel presentation (Infectious Personality) and one-on-one investor meetings

Presentation Date & Time: Wednesday, August 11, 2021, at 4:40 p.m. ET

The webcast of the Wedbush presentation will be accessible in the News & Events section of the Entasis website at https://www.entasistx.com/.

About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Company Contact:         

Kyle Dow

Entasis Therapeutics

(781) 810-0114

kyle.dow@entasistx.com

Investor Relations Contact:

Bruce Mackle

LifeSci Advisors

(929) 469-3859

bmackle@lifesciadvisors.com